Join
Live feed
·
PRReleasevia Quantisnow
Viracta Therapeutics Inc. logo

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

ByQuantisnow·Wall Street's wire, on your screen.
VIRX· Viracta Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VIRX (Viracta Therapeutics Inc.) and more on Quantisnow.